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Abstract
Significance: Enhanced levels of reactive oxygen species (ROS) have been associated with different disease
states. Most attempts to validate and exploit these associations by chronic antioxidant therapies have provided
disappointing results. Hence, the clinical relevance of ROS is still largely unclear. Recent Advances: We are
now beginning to understand the reasons for these failures, which reside in the many important physiological
roles of ROS in cell signaling. To exploit ROS therapeutically, it would be essential to define and treat the
disease-relevant ROS at the right moment and leave physiological ROS formation intact. This breakthrough
seems now within reach. Critical Issues: Rather than antioxidants, a new generation of protein targets for
classical pharmacological agents includes ROS-forming or toxifying enzymes or proteins that are oxidatively
damaged and can be functionally repaired. Future Directions: Linking these target proteins in future to specific
disease states and providing in each case proof of principle will be essential for translating the oxidative stress
concept into the clinic. Antioxid. Redox Signal. 23, 1171–1185.
Introduction
Reactive oxygen species (ROS) regulate several essen-tial physiological processes (63), including cell prolifer-
ation and differentiation, vascular tone, the innate immune
response, and inflammation (4, 63). Conversely, aberrant ROS
formation may trigger disease either by reaching concentra-
tions that exceed cellular antioxidant defense mechanisms or
by more subtle changes, such as ROS production in inappro-
priate cellular compartments (e.g., a subcellular localization
that physiologically does not produce ROS) or a shift in the
type of ROS being formed (e.g., superoxide instead of hy-
drogen peroxide) (32). This may then alone or in combination
with other factors contribute to various cardiovascular, (45)
neurological, or metabolic pathologies (48, 60, 147) or cancer
(32, 137), all diseases with high socioeconomical impact and
medical need (77).
Different pharmacological strategies have been pursued to
prevent or restore such supposedly systemic redox imbal-
ances and to improve disease outcomes, typically with
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antioxidant drugs or vitamins. However, intervention trials
with small molecules, especially antioxidants, have been
mostly ineffective (78) or even harmful (122). Hence, no
direct antioxidant approach is currently part of any evidence
guideline and the oxidative stress hypothesis still awaits
validation in humans.
One crucial reason for these failures may reside in the
dichotomy between disease-triggering and beneficial ROS
and differences in this between humans and animal models of
disease (132). To target redox-dependent diseases safely and
effectively, physiological ROS sources that are relevant for
signaling need to remain untouched, while disease-triggering
ROS should be effectively reduced.
Instead of antioxidants, a more recent and innovative ap-
proach uses pharmacological agents that selectively suppress
the activity of ROS-forming or toxifying enzymes (2, 3)
whose activity or expression is increased under pathological
conditions. These include the ROS generators, such as nitric
oxide synthase (NOS), monoamine oxidase (MAO), xanthine
oxidase (XO), and NADPH oxidase (NOX), or the ROS
toxifier, myeloperoxidase (MPO) (Fig. 1). In addition, we
will review a third and possibly synergistic strategy to
functionally repair proteins that have been damaged by ROS
(see related review by Dao et al. in this Forum on the New
ROS Pharmacology). It is also possible to reinforce redox
homeostasis by targeting the transcription factor Nrf2, a
master regulator of the antioxidant control (122). We jointly
review these ROS-based interventions of high clinical po-
tential and place them into context. However, all targets in-
cluded in this review are described at different levels based
on their clinical relevance and maturity in drug development.
Comparison between pharmacological inhibition of en-
zymes and changes observed in knockout (KO) animals is
detailed in the review. Inmost cases, a KO represents a de novo
deficiency possibly leading to adaptive responses. However,
most drug interventions are initiated after onset of the disease
(see related review byDao et al. in this Forum on the NewROS
Pharmacology). Therefore, although both approaches are not
always comparable, they are needed for targeting validation.
Physiology of ROS
While the existence of endogenous antioxidant enzymes
(i.e., superoxide dismutase, glutathione peroxidase, catalase)
suggests that the capacity to eliminate ROS is of evolutionary
benefit (121), evidence that ROS fulfill equally essential
FIG. 1. Sources and targets of reactive oxygen species. Largely beneficial enzymes or enzymes that downregulate
cyclic GMP (cGMP) signaling include nitric oxide synthase, Fe(II) heme-containing guanylate cyclase; PKG, cGMP-
dependent protein kinase; largely detrimental or cGMP downregulating enzymes, include uc-NOS, uncoupled, NOS apo-
sGC converted from sGC; PDE, phosphodiesterases; NOX, NADPH oxidase; MPO, myeloperoxidase; Mito, mitochondria;
LPO, lipid peroxidase; XO, xanthine oxidase converted from XD, xanthine dehydrogenase; MAO, monoamine oxidase.
Antioxidant proteins include SOD, superoxide dismutase; Nrf2, nuclear factor (erythroid-derived 2)-like 2; ARE, antiox-
idant response element; T/Prx, Thio/Peroxyredoxin. Drugs are depicted next to oblique lines (arrows indicate activation;
blocks, inhibition) either in bold (in clinical use: PDEi, PDE inhibitors; sGCs, sGC stimulators; NOd, NO donors; NOSr,
NOS recoupling agents; MAOi, monoamine oxidase inhibitors; XODi, XOD inhibitors) or italics (in pre/clinical devel-
opment: MPOi, MPO inhibitors; sGCa, sGC activators; NOSi, NOS inhibitors; Nrf2a, Nrf2 agonists; NOXi, NOX inhib-
itors). Proteins in the lower part indicate targets and biomarkers of cGMP and reactive oxygen species signaling: PPase,
phosphatases; TRP, transient receptor potential channels; Tyr/Trp-NO2
-, tyrosine or tryptophan-nitrated proteins; Tyr-Cl,
tyrosine-chlorinated proteins (38a).
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physiological functions stems from the existence of the NOX
enzyme family that has no other known function than to
produce ROS (72). Table 1 lists the major enzymatic sources
of ROS, ROS toxifiers, and their biological effects. Im-
portantly, these physiological effects, which can be ascribed
to a specific ROS source or toxifying enzyme, need to be kept
in mind as potential side effects of enzyme inhibitors during
chronic therapy.
From chemical antioxidants to defined enzyme targets
Antioxidants may have a benefit in acute parenteral treat-
ment, but evidence in chronic therapy is lacking (132). One
conceptual problem with the antioxidant approach is the fact
that it overlooks that ROS also may have beneficial effects.
Thus, scavenging ROS systemically may interfere with
physiological as well as with pathological processes. How-
ever, three alternative approaches to ROS scavenging have
been described, including the targeting of the relevant sour-
ces of ROS, ROS toxifiers, or repairing previously oxidized
proteins (e.g., oxidized soluble guanylate cyclase [sGC] or
endothelial nitric oxide synthase [eNOS]). In fact, targeting
disease-relevant enzymatic sources of ROS is one of the most
promising options. In this strategy, NOXs are a major target.
All other enzymes generate ROS together with other products
(e.g., MAO) or start to form ROS as a result of a biochemical
accident induced by their proteolytic or oxidative modifica-
tions. (125a) The latter include XO (57), uncoupled endo-
thelial NOS (uc-eNOS from eNOS) (95), and several
mitochondrial enzymes, particularly respiratory chain com-
plexes. Another important category of enzyme targets in-
cludes ROS toxifiers (70). We define them as enzymes that
convert relatively nontoxic ROS such as hydrogen peroxide
(H2O2) to more reactive species. A typical example is MPO,
which converts H2O2 into hypochlorous acid (HOCl) (150).
In a particular disease condition, specific inhibition of either
a source of ROS or an ROS toxifier may become an effective
and safe intervention. Recently, proof of principle has also been
shown for a surprising third alternative, that is, the functional
repair of oxidatively damaged proteins (see related review by
Dao et al. in this Forum on the New ROS Pharmacology).
These three approaches hold great therapeutic promise for
chronic therapy as long as they are optimally targeted, dosed,
and leave physiological ROS formation intact. All are cur-
rently in clinical development with the aim to (i) prevent
exacerbated ROS production by enzyme inhibition (NOX
and XO); (ii) prevent the toxification of ROS such as H2O2 to
secondary reactive products (e.g., byMPO); and (iii) promote
functional repair of proteins that were damaged by ROS.
However, these three approaches require thorough knowl-
edge about the target proteins in addition to possible phar-
macological inhibition (see related review by Dao et al. in
this Forum on the New ROS Pharmacology). In this review,
we focus on these target enzymes and the possible future
clinical indications for drugs targeting them.
Disease-Relevant Enzymatic Sources of ROS
NADPH oxidases
NOXs are multiprotein complexes, which contain six or
seven transmembrane-spanning domains (72). The NOX
enzyme family contains seven members, NOX1-5 and dual
oxidase (DUOX)1-2 (also termed NOX6-7). Each isoform
has a particular pattern of activity regulation, tissue expres-
sion, type of ROS produced, and function (Table 2) (12, 81).
The catalytic core of all NOXs contains one multimodular
NADPH binding site at the C-terminus and a bimodular flavin
adenine dinucleotide (FAD) binding site, as well as four
conserved histidine residues involved in the binding of two
heme moieties in the membrane. NOXs use NADPH as an
electron donor and proximal or extracellular oxygen as an
electron acceptor (27). Most NOX family members have
similar redox centers (68) as well as the mechanism to gen-
erate O2
- as the main product. However, NOX4 and DUOX
produce H2O2 as their primary product (86, 126). Other
membrane, cytosolic, and regulating domains are involved in
NOX activity. While NOX1-3 needs docking of cytosolic
factors for complete activation, NOX4 seems to produce
ROS constitutively. Yet, NOX5 and DUOX are activated by
elevated cellular Ca2+ concentrations via N-terminal EF-
hand domains (12).
Because NOX is the only known enzyme family with the
sole function to produce ROS (unlike XO, uc-eNOS, and
mitochondria), it may represent the primary disease mecha-
nism and thus targets for mechanism-based prevention of
oxidative damage (12, 110). Moreover, some NOX isoforms
are critically regulated by Ser/Thr kinases (e.g., PKC) (15),
although PKC itself is upregulated by ROS (74). Of the seven
isoforms, three are best studied: NOX1, NOX2, and NOX4.
NOX3 appears to have a very limited organ-specific role both
in physiology and pathophysiology. It is mostly expressed in
the vestibular system of the inner ear where it controls the
formation of otoconia, small biomineral particles (103).
Mutations affecting NOX3 activity have not been described
so far in humans, but its loss of function leads to severe
imbalance in the head tilt mouse (69). NOX5 is not expressed
in mice and rats and is thus understudied and remains the big
Table 1. Physiological Role of Reactive Oxygen
Species Sources and Reactive Oxygen
Species Toxifiers
Enzyme Function Potential side effect
NOX1 GI epithelial immune
defense
GI infections
NOX2 Innate immune
response
CGD, immune
suppression
NOX3 Otoconia formation Balance problems
NOX4 Angiogenesis Preconditioning,
increased sensitivity
to ischemic damage
NOX5 Sperm motility Male infertility,
immunosuppression
DUOX Thyroid hormone
formation
Thyroid suppression
MPO Immune defense Immune suppression
XO Catabolism
of purines
Mild
MAO Breakdown of
neurotransmitters
GI diseases and skin
reaction
Potential side effects of drugs targeting these enzymes.
CGD, chronic granulomatous disease; DUOX, dual oxidase; GI,
gastrointestinal; MAO, monoamine oxidase; MPO, myeloperox-
idase; NOX, nicotinamide adenine dinucleotide phosphate oxidase;
XO, xanthine oxidase.
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unknown when it comes to translating animal data toward
human pathology.
An involvement of NOX2 has been suggested in many
disease states (76). The complete loss of function of NOX2
results in chronic granulomatous disease (CGD), which is
characterized by susceptibility to certain fungal and bacterial
infections (120). Foremost, CGD carriers are prone to devel-
oping autoimmune diseases, such as polyarthritis and lupus
erythematosus (59, 120). Whether it may therefore become
a safety risk for pharmacological inhibition of NOX2 and
thereby compromise the innate immune response remains to
be tested.
With respect to NOX1, it seems to be implicated in sys-
temic hypertension (148). NOX1-deficient mice show a de-
creased angiotensin II-induced hypertensive response (42,
87). One study also found a significant effect of NOX1 de-
letion on basal blood pressure (43). Similarly, NOX1 over-
expression potentiates angiotensin II-induced hypertension
(31). NOX1-deficient mice were also protected from angio-
tensin II-induced aortic aneurysms (43) and diabetic vascu-
lopathies (Fig. 2), both in the retina (147) and in large vessel
atherosclerosis (48). Taken together, NOX1 may be involved
in a whole range of vascular diseases and remodeling of the
vascular wall.
NOX4 is the most widely distributed isoform and can also
contribute to diabetic end-organ damage, especially in the
kidney (60). NOX4 is also upregulated under hypoxic
conditions (94) and can function as an oxygen sensor (99).
Pathologically, stroke is one of the best-validated disease
indications for NOX4 inhibition (73, 109) (Fig. 2). Moreover,
NOX4 expression and activity are strongly increased fol-
lowing TGF-b stimulation of human fibroblasts. This can
lead to the transformation of not only normal fibroblasts into
myofibroblasts, a key feature of wound healing, but also of
chronic fibrotic diseases of the lungs, kidney, or liver. The
fact that NOX4 inhibition mitigates myofibroblast transfor-
mation in vitrowas first shown in cardiac and lung fibroblasts
(28, 53) and later in the bleomycin model of pulmonary
fibrosis using NOX4-deficient mice (23, 52). Interestingly,
the benefit of NOX4 inhibition appears to be tissue specific
as NOX4 deletion does not confer protection in urinary
obstruction-induced kidney fibrosis (8), a condition where
NOX4 inhibition even seems to be deleterious (100). Al-
though the direct connection of NOX4-derived ROS and the
tissue-specific fibroblast phenotypic changes are unclear,
NOX4 inhibition in idiopathic lung fibrosis represents an-
other promising indication for a pharmacological interven-
tion targeting NOX4.
Table 2. NOXs: Isoforms and Tissue Expression
Isoforms Tissue/cell expression Loss of function
Primary ROS
formed
NOX1 Colon, aorta Not reported (mouse KO has no obvious phenotype) O2
-
NOX2 Phagocytes, endothelium Susceptibility to infection (mouse, human),
inflammation (mouse, rat, human)
O2
-
NOX3 Inner ear Absence of otoconia (mouse, rat) O2
-
NOX4 Kidney, almost all tissues Not reported (mouse KO has no obvious phenotype) H2O2 O2
-
NOX5 Spleen, testis, endothelium Not reported (absent in rodents) O2
-
DUOX1/NOX6 Thyroid, gland, lung, epithelia Not reported (mouse KO has no phenotype) H2O2
DUOX2/NOX7 Thyroid, gland, lung, epithelia Hypothyroidism H2O2 (mouse, human)
DUOX, dual oxidase; O2
-, superoxide anion radical; H2O2, hydrogen peroxide; KO, knockout; NOX, nicotinamide adenine dinucleotide
phosphate oxidase; ROS, reactive oxygen species.
FIG. 2. Therapeutic indi-
cations for NOX inhibitors
and potential unwanted side
effects. Highly validated
physiological and pathological
roles of different NOX iso-
forms based on gene knock-
out experiments are based on
original data in stroke (73),
diabetic atherosclerosis (48),
diabetic nephropathy (60), di-
abetic retinopathy (147), and
osteoporosis (46a). For details,
see text. Based on this, NOXi
seem well suited in treating
acute ischemic stroke and di-
abetic complications.
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Finally, the NOX5 isoform, which is not expressed in mice
or rats (11), is unique as it is directly activated by calcium
(10) and may thus directly link cellular calcium overload
to oxidative stress. In adults, NOX5 is found mostly in the
spleen, lymph node, and the reproductive and vascular sys-
tems (39); in disease, it may play a role in coronary artery
disease (49).
DUOX enzymes are expressed at high levels in the thy-
roid glands and generate H2O2 at the apical membrane.
Mutations in DUOX2 and DUOXA2 lead to defects in
thyroidal H2O2 generation, congenital hypothyroidism, and
euthyroid goiter (61).
Despite the rich genetic evidence for distinct roles of dif-
ferent NOX isoforms (3), the development of isoform-specific
inhibitors is lagging behind (see related review byDao et al. in
this Forum on the New ROS Pharmacology). The first gen-
eration of inhibitors was highly unspecific, that is, not even
specific for NOX (56, 149), while, more recently, the achieved
differences in IC50 of the second-generation NOX-specific
compounds are hardly relevant in vivo (4). However, with the
increasing interest in this target both in pharmaceutical and
biotech industries, a third generation of inhibitors, specific and
isoform selective, is on the horizon (see related review by Dao
et al. in this Forum on the New ROS Pharmacology).
NOS
In this review, we consider nitric oxide (NO) a member of
the ROS family. NO is generated from l-arginine, contains an
unpaired electron (making it a free radical), and reacts with
O2
- in a diffusion-limited manner to form the highly reactive
peroxynitrite. Three NOS isoforms exist: NOS1 is predomi-
nantly present in the central and peripheral nervous system
(thus it is also named nNOS); NOS2, in macrophages; and
NOS3 in eNOS (123). Importantly, NOS3 has also to be
considered as a target of ROS, leading to reversible un-
coupling (see chapter below on proteins reversibly damaged
by ROS).
Mice with genetic deficiencies in one of the NOS isoforms
are viable. Nos1-/- mice show impaired cognitive perfor-
mance (145), dramatic enlargement of the stomach, and
significantly reduced brain damage after cerebral ischemia
(84). Nos2-/- mice suffer from impaired host defense against
pathogens and are prone to severe infections. However, they
are protected from life-threatening hypotension in septic
shock (84). Nos3-/- mice display impaired vasodilation, el-
evated blood pressure, diminished cardiac contractility (84),
and, under stress conditions, impaired adaptation, for exam-
ple, increased atherogenesis under high-fat diet and accel-
erated development of diabetic complications (18). Double
FIG. 3. VAS203 treatment against brain traumatic injury. (A) NADPH donates electrons to the reductase domain of
NOS. They are transferred via FAD and FMN to the oxygenase domain where they reduce heme-bound oxygen and an
intermediate role of BH4. Activated oxygen oxidizes a guanidine nitrogen of l-arginine to produce NO and l-citrulline (1a).
VAS203 is an analog of the physiological NOS cofactor tetrahydrobiopterin, which enables blockade of NOS activity.
VAS203 exhibits more suitable properties than other classical arginine NOS inhibitors (i.e., L-N6-Nitroarginine methyl ester
[L-NAME]). (B) VAS203-treated patients significantly reduced the therapeutic intensity level after a 6-day observation
period. (C) The median level in the extended Glasgow Outcome Score after 6 months was 1.5 score points higher under
VAS203 treatment compared with placebo (133). NOS, nitric oxide synthase. *Statistically significant difference between
VAS203 (30mg/kg) treatment and TL-placebo
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knockout mice that lack both NOS1 and NOS3 display ab-
normalities in hippocampal long-term potentiation, a model
for learning and memory (7). Triple knockout mice are se-
verely insulin resistant (nephrogenic diabetes insipidus),
display a number of cardiovascular risk factors, including
hypertension and hypertriglyceridemia, and develop sponta-
neous myocardial infarction, supporting a critical role of NO
in maintaining cardiovascular homeostasis (7, 138). Clini-
cally, many reports suggested therapeutic benefit from in-
hibiting NOS1 or NOS2, for example, asthma (51), migraine
(139), or cardiovascular diseases (CVDs) (2). Currently, the
clinically most advanced therapeutic approach for NOS in-
hibition is in traumatic brain injury (133) (Fig. 3).
XO
XO is defined as an enzyme activity; it utilizes oxygen as
the electron acceptor to form reduced ROS (89) according to
the following:
XanthineþH2OþO2/Uric acidþH2O2
XanthineþH2Oþ 2O2/Uric acidþ 2O2 þ 2Hþ
XO is derived from xanthine dehydrogenase (XDH, en-
coded by Xdh) by reversible sulfhydryl oxidation or by irre-
versible proteolytic modification (57, 98). As the terminal
enzyme in the catabolism of purines, XDH activity utilizes
NAD+ as the electron acceptor to convert hypoxanthine to
xanthine and the latter to uric acid, according to the following:
HypoxanthineþNADþ þH2O/XanthineþNADHþH
XanthineþNADþH2O/Uric acidþNADHþHþ
In some mammals, such as mice, uric acid is metabolized
further by uricase to form allantoin. As XO may arise from
XDH by sulfhydryl oxidation, XO activity can be a direct
consequence of increased oxidative stress that further con-
tributes to the pathogenesis of various diseases as a feed-
forward mechanism of ROS-induced ROS.
Homozygous Xdh-/-mice show early neonatal lethality and
display renal dysplasia (106), while heterozygous Xdh+/-mice
have disrupted formation of the milk fat globule, underlining
the importance of XDH to lactation (38). Reduced expression
of Xdh in mice augments lipid accumulation in adipocytes,
accompanied by an increase in oxidative stress, and induces
obesity with insulin resistance in older age groups (96).
Inhibition of XO has been clinically applied for decades
for the treatment of hyperuricemia and gout (35). In addition,
xanthine oxidase inhibitors (XOi) has recently been explored
for cardiovascular therapy (Fig. 4) based on animal (124, 135)
and clinical studies in patients with type 2 diabetes and idio-
pathic dilated cardiomyopathy (21, 22). While several studies
show clinical efficacy of XOi in CVD, others do not, such as in
the case of heart failure patients with hyperuricemia (46). A
possible explanation for these contradicting results is that XO
inhibition might be a double-edged sword. Thus, while XO
generates O2
-/H2O2 as by-products, its final metabolite, uric
acid, is also an antioxidant. Depending on the disease condition,
one of these opposite effects of XO (ROS or antioxidant pro-
duction) may prevail. This notion is consistent with the obser-
vation that plasma uric acid concentrations associate inversely
with some diseases (144), whereas they are independently and
significantly associated with other diseases (37).
MAO
MAOs are flavoenzymes (located at the outer mitochon-
drial membrane) that catalyze the oxidative deamination of
both endogenous and exogenous amines, including neuro-
transmitters and several drugs. They exist as two isoforms,
A and B, differing with respect to their tissue distribu-
tion, substrate preference, and inhibitor specificity (111).
MAO-A reacts preferentially with tyramine, serotonin, and
norepinephrine, while dopamine and phenylethylamine are
preferential substrates for MAO-B. The imine products are
coupled to the reduction of a covalently bound FAD, which in
turn is reoxidized by oxygen leading to H2O2. In mitochon-
dria, MAOs thus generate a significant percentage of total
H2O2 in addition to that formed by the electron transport
chain (5, 64). On the other hand, the imine product can also
spontaneously hydrolyze, generating the corresponding al-
dehyde and ammonia (33, 111). Of note, all the three products
of MAO catalysis are potentially toxic, especially at the level
of mitochondria (64). In this regard, H2O2 and aldehydes can
particularly synergize (62) leading to mitochondrial dys-
function. Moreover, they are directly related to endothelial
dysfunction, heart function, and muscular dystrophy (Fig. 5).
In addition, ammonia can stimulate further ROS formation by
dihydrolipoyl dehydrogenase, the E3 component of pyruvate
and oxoglutarate dehydrogenase (67).
Patients and mice lacking MAO-A activity are character-
ized by borderline mental retardation and aggressive behav-
ior (17, 19, 20), whereas polymorphisms in the MAO-A gene
have been associated with bipolar disorder (40, 83, 114). On
the other hand, variations in MAO-B activity in patients have
been associated with psychotic disorders, depression, im-
pulsivity, behavioral disinhibition, and attention-deficit/
hyperactivity disorder (1, 82, 85, 112). MAO inhibitors have
FIG. 4. Role of XO in ischemia–reperfusion-induced
oxidative stress. During ischemia, ATP causes accumulation
of its catabolite, hypoxanthine. Ischemia also induces con-
version of XD into XO. During reperfusion, with oxygen
available again, hypoxanthine is oxidized to uric acid, while
molecular oxygen is concomitantly reduced to O2
-. Scheme
derived from (89).
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been used for the treatment of affective disorders and their
mood-enhancing effect of MAO inhibition is likely related to
an increased availability of serotonin, norepinephrine, and
dopamine since their decrease is associated with depression
(154). Deficit in both MAO-A and -B activity causes severe
developmental and intellectual deficits, autistic-like behav-
ior, and stereotypical movements (25, 97, 127, 128, 146).
The emphasis on MAO substrates (i.e., neurotransmitters)
has curtailed the attention on the relevance of MAO products.
Increased MAO-B activity has been correlated with Parkin-
son’s disease (13, 66, 117). MAO expression increases in
aging (88, 118) and an increased expression is associated
with endothelial dysfunction (134), postoperative atrial fibril-
lation, muscular dystrophy (91), and prostate cancer (152). A
common denominator among all these pathologies is altered
ROS. In agreement with this, beneficial effects of MAO in-
hibition have been demonstrated in these conditions as well
as in myocardial ischemia/reperfusion injury (14, 30), heart
failure (62, 65, 140), and neurodegenerative disorders (16).
ROS Toxifiers
ROS toxifiers include different peroxidases such us eo-
sinophil peroxidase, lactoperoxidase, and thyroid peroxidase.
These enzymes share several similarities with their ortholog,
MPO. However, here we mainly focus on MPO due to its
clinical relevance and promising preclinical data.
MPO
MPO, a heme peroxidase present in circulating neutrophils,
monocytes, and some tissue macrophages, plays an important
role in killing invading microbes (71). MPO generates a
number of reactive chlorinating and brominating oxidants,
including nonradical species (two-electron oxidants) and rad-
ical species (50). In fact, MPO acts as a toxifier since in the
presence of halides (Cl-, Br-), it transforms the relativelyweak
two-electron oxidant H2O2 into the more reactive hypohalous
acids, (hypochlorous acid, [HOCl]; and hypobromous acid,
[HOBr]) (150), as well as chloramines (104). MPO is also a
major contributor to protein nitration since inflamed tissues of
MPO-deficient mice contain significantly less 3-nitrotyrosine
than those inwild-typemice (41). In addition to their role in the
innate immune response, MPO-derived oxidants have the
potential to cause host tissue injury by promoting post-
translational protein modification (107, 150) and lipid oxida-
tion (119). MPO was demonstrated to promote CVD and
pharmacological inhibition or genetic deletion partially pre-
vented these adverse effects (79, 141). However, it should be
noted that MPO also fulfills an important role in host defense
against pathogens and genetic deletion increased the severity
of infections in animal models, although no clear increase in
susceptibility to infections was observed in humans withMPO
polymorphisms (34). Therefore, although MPO is detrimental
in the context of CVDs, it also plays a major role in defense
against pathogens, thus partial inhibition may be better than
a complete blockage of the enzyme (see related review by
Dao et al. in this Forum on the New ROS Pharmacology).
MPO is predominately located in inflamed tissue where it
is found within or nearby infiltrated neutrophils and certain
macrophages. Upon activation, phagocytes release MPO. In
the case of circulating neutrophils, released MPO can
bind to the endothelium, translocate, and be deposited in the
subendothelial space (101). As a consequence of its localization
and production of highly reactive oxidants, MPO is thought to
contribute to a wide range of chronic inflammatory diseases as
well as cardiovascular and neuroinflammatory diseases.
In addition to inhibiting MPO activity directly, an alter-
native therapeutic strategy is to displace MPO from the
vascular endothelium and subendothelial space, that is, the
sites where MPO released from circulating phagocytes is
thought to bind to and reside. MPO binds to endothelial
cells via heparin sulfate glycosaminoglycan, and heparin
prevents and reverses such binding (9). The removal of
MPO by heparin may help explain its anti-inflammatory
actions. In fact, infusion of heparin increases the plasma
concentration of MPO and increases flow-mediated dilata-
tion (115), a major indicator of endothelial nitric oxide
bioavailability.
Targeting MPO is in the early stages of clinical devel-
opment, for example, as treatment for neurodegenerative,
cardiovascular, and pulmonary diseases. Therefore, the next
few years will be crucial in providing a definitive answer
on whether inhibition of this toxifier enzyme is a valid
strategy for preventing or alleviating various inflammatory
diseases.
FIG. 5. Schematic representation of the mechanisms
underlying the contribution of MAO activity to patho-
logical conditions. Although the scheme focuses on car-
diovascular and muscular diseases, especially heart failure,
endothelial dysfunction, or muscular dystrophy, similar
pathological mechanisms based upon mitochondrial dys-
function are likely to act also in other organs.
ROS-RELATED DISEASES: TARGETS AND INDICATIONS 1177
Proteins Damaged by ROS
In addition to preventing ROS-induced damage, its func-
tional repair is much more than an option and has already
entered clinical practice. A key example of this is impaired
NO-cyclic guanosine monophosphate (cGMP) signaling.
uc-eNOS, NO scavenging, and apo-sGC
NO is an important cellular signaling molecule, which is
involved in many physiological processes (58). NO production
and ROS activate PKC, which contributes to cellular prolifera-
tion, neoplasia, and cancer (75, 113). Besides, NO interacts with
different receptors (i.e., NMDAR and G-protein-coupled re-
ceptors) promoting the release of zinc ions from metallothio-
neins mediated by the nNOS/NO pathway (116). Accumulation
of zinc is related to mood disorders, schizophrenia, and both
neurological and neurodegenerative diseases (108).
However, almost all physiological effects of NO are medi-
ated through its receptor enzyme, sGC, a heterodimeric heme
protein comprising of a larger a subunit and a smaller heme-
binding b subunit. Upon binding of NO to sGC heme, the
conversion of guanosine-5¢-triphosphate to the intracellular
signaling molecule, cGMP, is activated. cGMP in turn regu-
lates cGMP-dependent protein kinases and ion channels and is
degraded by phosphodiesterases (29). The resulting effects
include (acutely) inhibition of blood vessel contraction, im-
proved perfusion, antithrombosis, neurotransmission, and
memory formation, as well as (chronically) antiproliferation,
antiremodeling, and anti-inflammation effects (123).
Oxidative stress can lead to the deregulation of NO-cGMP
signaling (90) either by oxidizing and uncoupling NOS, by
chemical scavenging of NO, or by oxidation and loss of heme
in sGC. NOS3/eNOS, NOS1/nNOS (93), and to a lesser extent
NOS2/iNOS (153) can be oxidatively damaged. This involves
a highly redox-sensitive cofactor, tetrahydrobiopterin (H4B).
In uc-NOS, oxygen activation is uncoupled from arginine-to-
NO metabolism and NOSs become themselves ROS-forming
enzymes; another example of ROS-induced ROS formation.
Impaired NO-sGC-cGMP signaling can thus be caused by
reduced NO bioavailability and/or decreased responsiveness
to NO and has been implicated in the pathogenesis of many
cardiovascular, pulmonary, endothelial, renal, and neuro-
logical diseases (90, 148). Clinical evidence for a role of
oxidative H4B depletion is based on recoupling and im-
provement of endothelial function in chronic smokers by
BH4, but not by tetrahydroneopterin (H4N), which shares the
antioxidant properties of H4B, but is not a cofactor for NOS3/
eNOS (54, 55). Likewise, supplementation with the BH4
analog, folic acid, improves endothelial function in human
subjects (6, 47). In fact, in experimental hypertension as
well as atherosclerosis treatment with the H4B precursor,
sepiapterin restores endothelial function (80, 125). In addi-
tion, many studies have reported a positive effect of l-
arginine supplementation in endothelial dysfunction (136).
This is surprising as arginine plasma levels by far exceed the
Km of eNOS for l-arginine. A possible explanation for the
protective effects of high-dose l-arginine administration may
reside in the competition of l-arginine with an endogenous
competitive inhibitor at the l-arginine binding site, asym-
metric dimethyl l-arginine (ADMA), or the normaliza-
tion of intracellular ADMA levels (24). Because of lower
bioavailability of l-arginine in humans versus rodents,
Table 3. Pathological Role of Enzymatic Reactive Oxygen Species Sources
and Their Current Clinical Status
Target Pathology Current status of clinical translation
NOX Type 2 diabetes mellitus associated with
diabetic nephropathy (68)
Reduction in both liver enzyme and inflammatory marker
levels, primary efficacy endpoints, albuminuria,
not achieved (NCT 02010242)
NOS Septic shock (91) Failure in treatment against septic shock (91)
Asthma (58) No improvement of respiratory functions (58)
Acute migraine (66, 145) Ineffective in the treatment of acute migraine (66, 145)
Cardiogenic shock complicating acute
myocardial infarction (2)
Did not reduce mortality in patients with refractory
cardiogenic shock (2)
Traumatic brain injury (139) Phase II clinical trial complete
XO CVD (129, 141), type 2 diabetes (24, 25) Improves endothelial function in patients with CVD (64)
Gout (12) More effective than allopurinol in gout patients
(12, 13, 27)
MPO Multiple sclerosis and COPD (28) Phase I clinical trial for COPD and multiple sclerosis
Parkinson’s disease (115) Phase IIA clinical trial in patients with Parkinson’s
disease
CVD (89) Positive results in preclinical animal models (89)
NOS CVD Reverses pulmonary hypertension (43)
sGC PAH (18) Entered in the clinic (18, 52)
Heart failure (112) Phase II clinical trial. Still open—recruiting
Acute heart failure (51) Still in clinical development. Phase IIb clinical trial
complete (40, 51)
Acute heart failure (51) Still in clinical development
MAO Parkinson’s disease, dementia, and depression (5) In the clinic
Parkinson’s disease, dementia, and depression (5) In the clinic
CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; MAO, monoamine oxidase; MPO, myeloperoxidase; NOS,
nitric oxide synthase; NOX, nicotinamide adenine dinucleotide phosphate oxidase; PAH, pulmonary arterial hypertension; sGC, soluble
guanylate cyclase; XO, xanthine oxidase.
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l-citrulline may be a better alternative and is subject to on-
going trials (Australian New Zealand Clinical Trials Registry
ACTRN12609000882224).
In addition to NOS, ROS can also affect the bioavailability
of NO by direct chemical scavenging and the redox state of
sGC resulting in the oxidation of its heme iron to Fe3+ and/or
ultimately in loss of the sGCheme (36, 131). The resulting apo-
sGC is completely unresponsive to NO and rapidly degrades
(92). Both pathomechanisms can be functionally reversed. So-
called sGC stimulators sensitize sGC for lower NO concen-
trations to yield the same cGMP stimulatory effects as physi-
ological NO levels would cause; sGC activators bind to the
oxidized/heme-free form of sGC and reactivate the enzyme to
the same Vmax levels as NO-stimulated heme-containing sGC.
sGC stimulators have entered the clinic. The PATENT-1
and PATENT-2 clinical trials in pulmonary arterial hyper-
tension patients showed an increased walking distance (45).
Moreover, the CHEST-1 trial in chronic thromboembolic
pulmonary hypertension, for which otherwise pulmonary
endarterectomy has been the only other curative option,
showed improved exercise capacity, mean pulmonary artery
pressure, cardiac output, and decreased clinically relevant
pulmonary vascular resistance. A second sGC stimulator,
vericiguat, is now in clinical development for different forms
of heart failure (105). In addition, preclinical data suggest
that sGC stimulators may be of benefit in chronic kidney
disease (130) and hypertension (26, 129, 142, 143).
The development of sGC activators lags behind that of
sGC stimulators due to initial pharmacokinetic setbacks (44),
but preclinical data suggest benefit in cardiac hypertrophy
(26) and type 2 diabetic nephropathy (102). Importantly,
these effects seem to occur at doses that do not affect mean
arterial pressure and heart rate and may thus involve prefer-
ential microvascular dilation.
Conclusions
For several decades redox imbalances have been suggested
to have relevance in neurodegenerative, cardiovascular,
metabolic, and neoplastic diseases. Therapeutically, most
attempts to translate ROS scavenging by antioxidants into the
clinic have yielded mostly disappointing results. However,
pharmacological modulation of protein targets to either de-
crease ROS overproduction or toxification, as well as func-
tional reversal of ROS-induced damage, has lead to several
therapeutic breakthroughs (Table 3).
Outlook
With the introduction of sGC stimulators for pulmonary
hypertension, repurposing of XOi and monoamine oxidase
inhibitors for ROS-related cardiovascular indications and the
successful development of several new principles such as
NOXi, MPOi, and NOSi into phase III translational ROS
research are at the verge of major breakthroughs. Several of
these candidate compounds are currently in clinical devel-
opment and are likely to dramatically reshape the perception
of the field of ROS and oxidative stress.
Acknowledgments
A.I.C., A.D., F.D.L., V.J., T.S., K.H.K., M.G.L., A.C.,
P.G., and H.H.H.W.S. were supported by the European
Cooperation in Science and Technology (COST Action
BM1203/EU-ROS). N.K. is supported by an EFSD/Sanofi
Award. H.H.H.W.S. is the recipient of an ERC Advanced
Grant and a Marie Curie IRG. R.S. is supported by a Senior
Principal Research Fellowship from the National Health and
Medical Research Council of Australia.
References
1. Adolfsson R, Gottfries CG, Oreland L, Wiberg A, and
Winblad B. Increased activity of brain and platelet
monoamine oxidase in dementia of Alzheimer type. Life
Sci 27: 1029–1034, 1980.
1a. Alderton WK, Cooper CE, and Knowles RG. Nitric oxide
synthases: structure, function and inhibition. Biochem J
357: 593–615, 2001.
2. Alexander JH, Reynolds HR, Stebbins AL, Dzavik V,
Harrington RA, Van de Werf F, and Hochman JS. Effect
of tilarginine acetate in patients with acute myocardial
infarction and cardiogenic shock: the TRIUMPH ran-
domized controlled trial. JAMA 297: 1657–1666, 2007.
3. Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P,
Rob Hermans JJ, Schiffers P, Ho H, Wingler K, and
Schmidt HH. The NOX toolbox: validating the role of
NADPH oxidases in physiology and disease. Cell Mol Life
Sci 69: 2327–2343, 2012.
4. Altenhofer S, Radermacher KA, Kleikers PW, Wingler K,
and Schmidt HH. Evolution of NADPH oxidase inhibi-
tors: selectivity and mechanisms for target engagement.
Antioxid Redox Signal 23: 406–427, 2015.
5. Anderson EJ, Efird JT, Davies SW, O’Neal WT, Darden
TM, Thayne KA, Katunga LA, Kindell LC, Ferguson TB,
Anderson CA, Chitwood WR, Koutlas TC, Williams JM,
Rodriguez E, and Kypson AP. Monoamine oxidase is a
major determinant of redox balance in human atrial
myocardium and is associated with postoperative atrial
fibrillation. J Am Heart Assoc 3: e000713, 2014.
6. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J,
Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R,
Refsum H, and Channon KM. 5-methyltetrahydrofolate
rapidly improves endothelial function and decreases
superoxide production in human vessels: effects on vascular
tetrahydrobiopterin availability and endothelial nitric oxide
synthase coupling. Circulation 114: 1193–1201, 2006.
7. Atochin DN and Huang PL. Endothelial nitric oxide
synthase transgenic models of endothelial dysfunction.
Pflugers Arch 460: 965–974, 2010.
8. Babelova A, Avaniadi D, Jung O, Fork C, Beckmann J,
Kosowski J, Weissmann N, Anilkumar N, Shah AM,
Schaefer L, Schroder K, and Brandes RP. Role of Nox4 in
murine models of kidney disease. Free Radic Biol Med
53: 842–853, 2012.
9. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M,
Chumley P, Ma W, Tousson A, White CR, Bullard DC,
Brennan M-L, Lusis AJ, Moore KP, and Freeman BA.
Endothelial transcytosis of myeloperoxidase confers
specificity to vascular ECM proteins as targets of tyrosine
nitration. J Clin Invest 108: 1759–1770, 2001.
10. Banfi B, Molnar G, Maturana A, Steger K, Hegedus B,
Demaurex N, and Krause KH. A Ca(2+)-activated
NADPH oxidase in testis, spleen, and lymph nodes. J Biol
Chem 276: 37594–37601, 2001.
11. Bedard K, Jaquet V, and Krause KH. NOX5: from basic
biology to signaling and disease. Free Radic Biol Med 52:
725–734, 2012.
ROS-RELATED DISEASES: TARGETS AND INDICATIONS 1179
12. Bedard K and Krause KH. The NOX family of ROS-
generating NADPH oxidases: physiology and pathophys-
iology. Physiol Rev 87: 245–313, 2007.
13. Bialecka M, Klodowska-Duda G, Honczarenko K,
Gawronska-Szklarz B, Opala G, Safranow K, and
Drozdzik M. Polymorphisms of catechol-0-methyltransferase
(COMT), monoamine oxidase B (MAOB), N-
acetyltransferase 2 (NAT2) and cytochrome P450 2D6
(CYP2D6) gene in patients with early onset of Parkin-
son’s disease. Parkinsonism Relat Disord 13: 224–229,
2007.
14. Bianchi P, Kunduzova O, Masini E, Cambon C, Bani D,
Raimondi L, Seguelas MH, Nistri S, Colucci W, Leducq
N, and Parini A. Oxidative stress by monoamine oxidase
mediates receptor-independent cardiomyocyte apoptosis
by serotonin and postischemic myocardial injury. Circu-
lation 112: 3297–3305, 2005.
15. Bokoch GM, Diebold B, Kim JS, and Gianni D. Emerging
evidence for the importance of phosphorylation in the
regulation of NADPH oxidases. Antioxid Redox Signal 11:
2429–2441, 2009.
16. Bortolato M, Chen K, and Shih JC. Monoamine oxidase
inactivation: from pathophysiology to therapeutics. Adv
Drug Deliv Rev 60: 1527–1533, 2008.
17. Bortolato M and Shih JC. Behavioral outcomes of
monoamine oxidase deficiency: preclinical and clinical
evidence. Int Rev Neurobiol 100: 13–42, 2011.
18. Bressler J, Pankow JS, Coresh J, and Boerwinkle E.
Interaction between the NOS3 gene and obesity as a
determinant of risk of type 2 diabetes: the athero-
sclerosis risk in communities study. PLoS One 8: e79466,
2013.
19. Brunner HG, Nelen M, Breakefield XO, Ropers HH, and
van Oost BA. Abnormal behavior associated with a point
mutation in the structural gene for monoamine oxidase A.
Science 262: 578–580, 1993.
20. Brunner HG, Nelen MR, van Zandvoort P, Abeling NG,
van Gennip AH, Wolters EC, Kuiper MA, Ropers HH,
and van Oost BA. X-linked borderline mental retardation
with prominent behavioral disturbance: phenotype, ge-
netic localization, and evidence for disturbed monoamine
metabolism. Am J Hum Genet 52: 1032–1039, 1993.
21. Butler R, Morris AD, Belch JJ, Hill A, and Struthers AD.
Allopurinol normalizes endothelial dysfunction in type 2
diabetics with mild hypertension. Hypertension 35: 746–
751, 2000.
22. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO,
Kobeissi ZA,Marban E, and Hare JM. Allopurinol improves
myocardial efficiency in patients with idiopathic dilated
cardiomyopathy. Circulation 104: 2407–2411, 2001.
23. Carnesecchi S, Deffert C, Donati Y, Basset O, Hinz B,
Preynat-Seauve O, Guichard C, Arbiser JL, Banfi B,
Pache JC, Barazzone-Argiroffo C, and Krause KH. A
key role for NOX4 in epithelial cell death during de-
velopment of lung fibrosis. Antioxid Redox Signal 15:
607–619, 2011.
24. Closs EI, Ostad MA, Simon A, Warnholtz A, Jabs A,
Habermeier A, Daiber A, Forstermann U, and Munzel T.
Impairment of the extrusion transporter for asymmetric
dimethyl-l-arginine: a novel mechanism underlying va-
sospastic angina. Biochem Biophys Res Commun 423:
208–223, 2012.
25. Collins FA, Murphy DL, Reiss AL, Sims KB, Lewis JG,
Freund L, Karoum F, Zhu D, Maumenee IH, and Anto-
narakis SE. Clinical, biochemical, and neuropsychiatric
evaluation of a patient with a contiguous gene syndrome
due to a microdeletion Xp11.3 including the Norrie dis-
ease locus and monoamine oxidase (MAOA and MAOB)
genes. Am J Med Genet 42: 127–134, 1992.
26. Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ,
Morgan LA, Maniscalco K, Olzinski AR, Ballard VL,
Herry K, Grondin P, Dodic N, Mirguet O, Bouillot A,
Gellibert F, Coatney RW, Lepore JJ, Jucker BM,
Jolivette LJ, Willette RN, Schnackenberg CG, and
Behm DJ. Comparison of soluble guanylate cyclase
stimulators and activators in models of cardiovascular
disease associated with oxidative stress. Front Phar-
macol 3: 128, 2012.
27. Cross AR and Segal AW. The NADPH oxidase of pro-
fessional phagocytes—prototype of the NOX electron
transport chain systems. Biochim Biophys Acta 1657:
1–22, 2004.
28. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S,
Dikalov S, and Sorescu D. NAD(P)H oxidase 4 mediates
transforming growth factor-beta1-induced differentiation
of cardiac fibroblasts into myofibroblasts. Circ Res 97:
900–907, 2005.
29. Derbyshire ER and Marletta MA. Structure and regulation
of soluble guanylate cyclase. Annu Rev Biochem 81: 533–
559, 2012.
30. Di Lisa F, Kaludercic N, Carpi A, Menabo R, and
Giorgio M. Mitochondrial pathways for ROS formation
and myocardial injury: the relevance of p66(Shc) and
monoamine oxidase. Basic Res Cardiol 104: 131–139,
2009.
31. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J,
Dikalov S, San Martin A, Lyle A, Weber DS, Weiss D,
Taylor WR, Schmidt HH, Owens GK, Lambeth JD, and
Griendling KK. Nox1 overexpression potentiates angio-
tensin II-induced hypertension and vascular smooth
muscle hypertrophy in transgenic mice. Circulation 112:
2668–2676, 2005.
32. Droge W. Free radicals in the physiological control of cell
function. Physiol Rev 82: 47–95, 2002.
33. Edmondson DE, Mattevi A, Binda C, Li M, and Hubalek
F. Structure and mechanism of monoamine oxidase. Curr
Med Chem 11: 1983–1993, 2004.
34. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C,
Tousson A, Castro L, Lusis AJ, Nauseef WM, White
CR, and Freeman BA. Myeloperoxidase, a leukocyte-
derived vascular NO oxidase. Science 296: 2391–2394,
2002.
35. Elion GB. The purine path to chemotherapy. Science 244:
41–47, 1989.
36. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt
HH, and Stasch JP. NO-independent stimulators and
activators of soluble guanylate cyclase: discovery and
therapeutic potential. Nat Rev Drug Discov 5: 755–768,
2006.
37. Fang J and Alderman MH. Serum uric acid and cardio-
vascular mortality the NHANES I epidemiologic follow-
up study, 1971–1992. National Health and Nutrition Ex-
amination Survey. JAMA 283: 2404–2410, 2000.
38. Fini MA, Monks J, Farabaugh SM, and Wright RM.
Contribution of xanthine oxidoreductase to mammary
epithelial and breast cancer cell differentiation in part
modulates inhibitor of differentiation-1. Mol Cancer Res
9: 1242–1254, 2011.
1180 CASAS ET AL.
38a. Frijhoff J WPG, Stocker R, Cheng D, Davies SS, Knight
A, Taylor E, Ruskovska T, Gasparovic AC, Oettrich J,
Zarkovic N, Weber D, Poulsen HE, Cuadrado A, Grune T,
Schmidt HH, and Ghezzi P. Clinical relevance of bio-
markers of oxidative stress. Antioxid Redox Signal 23:
1144–1170, 2015.
39. Fulton DJ. Nox5 and the regulation of cellular function.
Antioxid Redox Signal 11: 2443–2452, 2009.
40. Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES,
and Rubinsztein DC. Analysis of the monoamine oxidase
A (MAOA) gene in bipolar affective disorder by associ-
ation studies, meta-analyses, and sequencing of the pro-
moter. Am J Med Genet 88: 398–406, 1999.
41. Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA,
Hotchkiss RS, Belaaouaj A, and Heinecke JW. Myelo-
peroxidase produces nitrating oxidants in vivo. J Clin
Invest 109: 1311–1319, 2002.
42. Gavazzi G, Banfi B, Deffert C, Fiette L, Schappi M,
Herrmann F, and Krause KH. Decreased blood pressure in
NOX1-deficient mice. FEBS Lett 580: 497–504, 2006.
43. Gavazzi G, Deffert C, Trocme C, Schappi M, Herrmann
FR, and Krause KH. NOX1 deficiency protects from
aortic dissection in response to angiotensin II. Hyperten-
sion 50: 189–196, 2007.
44. Gheorghiade M, Greene SJ, Filippatos G, Erdmann E,
Ferrari R, Levy PD, Maggioni A, Nowack C, and Meba-
zaa A. Cinaciguat, a soluble guanylate cyclase activator:
results from the randomized, controlled, phase IIb
COMPOSE programme in acute heart failure syndromes.
Eur J Heart Fail 14: 1056–1066, 2012.
45. Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert
M, Jing ZC, Keogh AM, Langleben D, Kilama MO,
Fritsch A, Neuser D, and Rubin LJ. Riociguat for the
treatment of pulmonary arterial hypertension. N Engl J
Med 369: 330–340, 2013.
46. Givertz MM, Anstrom KJ, Redfield MM, Deswal A,
Haddad H, Butler J, TangWH, Dunlap ME, LeWinter MM,
Mann DL, Felker GM, O’Connor CM, Goldsmith SR, Ofili
EO, Saltzberg MT, Margulies KB, Cappola TP, Konstam
MA, Semigran MJ, McNulty SE, Lee KL, Shah MR, and
Hernandez AF. Effects of xanthine oxidase inhibition in
hyperuricemic heart failure patients: the xanthine oxidase
inhibition for hyperuricemic heart failure patients
(EXACT-HF) study. Circulation 131: 1763–1771, 2015.
46a. Goettsch C, Babelova A, Trummer O, Erben RG, Rauner
M, Rammelt S, Weissmann N, Weinberger V, Benkhoff S,
Kampschulte M, Obermayer-Pietsch B, Hofbauer LC,
Brandes RP, and Schroder K. NADPH oxidase 4 limits
bone mass by promoting osteoclastogenesis. J Clin Invest
123: 4731–4738, 2013.
47. Gori T, Burstein JM, Ahmed S, Miner SE, Al-Hesayen A,
Kelly S, and Parker JD. Folic acid prevents nitroglycerin-
induced nitric oxide synthase dysfunction and nitrate toler-
ance: a human in vivo study. Circulation 104: 1119–1123.,
2001.
48. Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F,
Montezano AC, de Haan JB, Koulis C, El-Osta A, Andrews
KL, Chin-Dusting JP, Touyz RM, Wingler K, Cooper ME,
Schmidt HH, and Jandeleit-Dahm KA. NADPH oxidase 1
plays a key role in diabetes mellitus-accelerated athero-
sclerosis. Circulation 127: 1888–1902, 2013.
49. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE,
Mangalat D, Hoch N, Dikalov S, Rudzinski P, Kapelak
B, Sadowski J, and Harrison DG. Calcium-dependent
NOX5 nicotinamide adenine dinucleotide phosphate
oxidase contributes to vascular oxidative stress in hu-
man coronary artery disease. J Am Coll Cardiol 52:
1803–1809, 2008.
50. Hampton MB, Kettle AJ, and Winterbourn CC. Inside the
neutrophil phagosome: oxidants, myeloperoxidase, and
bacterial killing. Blood 92: 3007–3017, 1998.
51. Hansel TT, Kharitonov SA, Donnelly LE, Erin EM, Currie
MG, Moore WM, Manning PT, Recker DP, and Barnes
PJ. A selective inhibitor of inducible nitric oxide synthase
inhibits exhaled breath nitric oxide in healthy volunteers
and asthmatics. FASEB J 17: 1298–1300, 2003.
52. Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A,
Bernard K, Hock T, Meldrum E, Sanders YY, and
Thannickal VJ. Reversal of persistent fibrosis in aging by
targeting Nox4-Nrf2 redox imbalance. Sci Transl Med 6:
231ra47, 2014.
53. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR,
Horowitz JC, Pennathur S, Martinez FJ, and Thannickal
VJ. NADPH oxidase-4 mediates myofibroblast activation
and fibrogenic responses to lung injury. Nat Med 15:
1077–1081, 2009.
54. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau
H, Henne S, Meinertz T, and Munzel T. Tetra-
hydrobiopterin improves endothelium-dependent vasodi-
lation in chronic smokers: evidence for a dysfunctional
nitric oxide synthase. Circ Res 86: E36–E41, 2000.
55. Heitzer T, Krohn K, Albers S, and Meinertz T. Tetra-
hydrobiopterin improves endothelium-dependent vasodi-
lation by increasing nitric oxide activity in patients with
Type II diabetes mellitus. Diabetologia 43: 1435–1438,
2000.
56. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH,
Busse R, Schroder K, and Brandes RP. Apocynin is not an
inhibitor of vascular NADPH oxidases but an antioxidant.
Hypertension 51: 211–217, 2008.
57. Hille R and Nishino T. Flavoprotein structure and mech-
anism. 4. Xanthine oxidase and xanthine dehydrogenase.
FASEB J 9: 995–1003, 1995.
58. Hou YC, Janczuk A, and Wang PG. Current trends in the
development of nitric oxide donors. Curr Pharm Des 5:
417–441, 1999.
59. Hultqvist M, Olsson LM, Gelderman KA, and Holmdahl
R. The protective role of ROS in autoimmune disease.
Trends Immunol 30: 201–208, 2009.
60. Jha JC, Gray SP, Barit D, Okabe J, El-Osta A, Namikoshi
T, Thallas-Bonke V, Wingler K, Szyndralewiez C, Heitz
F, Touyz RM, Cooper ME, Schmidt HH, and Jandeleit-
Dahm KA. Genetic targeting or pharmacologic inhibi-
tion of NADPH oxidase nox4 provides renoprotection in
long-term diabetic nephropathy. J Am Soc Nephrol 25:
1237–1254, 2014.
61. Johnson KR, Marden CC, Ward-Bailey P, Gagnon LH,
Bronson RT, and Donahue LR. Congenital hypothyroid-
ism, dwarfism, and hearing impairment caused by a mis-
sense mutation in the mouse dual oxidase 2 gene, Duox2.
Mol Endocrinol 21: 1593–1602, 2007.
62. Kaludercic N, Carpi A, Nagayama T, Sivakumaran V,
Zhu G, Lai EW, Bedja D, De Mario A, Chen K,
Gabrielson KL, Lindsey ML, Pacak K, Takimoto E, Shih
JC, Kass DA, Di Lisa F, and Paolocci N. Monoamine
oxidase B prompts mitochondrial and cardiac dysfunc-
tion in pressure overloaded hearts. Antioxid Redox Signal
20: 267–280, 2014.
ROS-RELATED DISEASES: TARGETS AND INDICATIONS 1181
63. Kaludercic N, Deshwal S, and Di Lisa F. Reactive oxygen
species and redox compartmentalization. Front Physiol 5:
285, 2014.
64. Kaludercic N, Mialet-Perez J, Paolocci N, Parini A, and
Di Lisa F. Monoamine oxidases as sources of oxidants in
the heart. J Mol Cell Cardiol 73: 34–42, 2014.
65. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai
EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih
JC, Pacak K, Kass DA, Di Lisa F, and Paolocci N.
Monoamine oxidase A-mediated enhanced catabolism of
norepinephrine contributes to adverse remodeling and
pump failure in hearts with pressure overload. Circ Res
106: 193–202, 2010.
66. Kang SJ, Scott WK, Li YJ, Hauser MA, van der Walt JM,
Fujiwara K, Mayhew GM, West SG, Vance JM, and
Martin ER. Family-based case-control study of MAOA
and MAOB polymorphisms in Parkinson disease. Mov
Disord 21: 2175–2180, 2006.
67. Kareyeva AV, Grivennikova VG, Cecchini G, and
Vinogradov AD. Molecular identification of the enzyme
responsible for the mitochondrial NADH-supported
ammonium-dependent hydrogen peroxide production.
FEBS Lett 585: 385–389, 2011.
68. Kawahara T, Quinn MT, and Lambeth JD. Molecular
evolution of the reactive oxygen-generating NADPH ox-
idase (Nox/Duox) family of enzymes. BMC Evol Biol 7:
109, 2007.
69. Kiss PJ, Knisz J, Zhang Y, Baltrusaitis J, Sigmund CD,
Thalmann R, Smith RJ, Verpy E, and Banfi B. Inactiva-
tion of NADPH oxidase organizer 1 results in severe
imbalance. Curr Biol 16: 208–213, 2006.
70. Klebanoff SJ. Myeloperoxidase-halide-hydrogen peroxide
antibacterial system. J Bacteriol 95: 2131–2138, 1968.
71. Klebanoff SJ. Oxygen metabolism and the toxic prop-
erties of phagocytes. Ann Intern Med 93: 480–489,
1980.
72. Kleikers PW, Wingler K, Hermans JJ, Diebold I, Alten-
hofer S, Radermacher KA, Janssen B, Gorlach A, and
Schmidt HH. NADPH oxidases as a source of oxidative
stress and molecular target in ischemia/reperfusion injury.
J Mol Med (Berl) 90: 1391–1406, 2012.
73. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones
E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, Barthel
K, Schuhmann MK, Herrmann AM, Meuth SG, Stoll G,
Meurer S, Schrewe A, Becker L, Gailus-Durner V, Fuchs
H, Klopstock T, de Angelis MH, Jandeleit-Dahm K, Shah
AM, Weissmann N, and Schmidt HH. Post-stroke inhi-
bition of induced NADPH oxidase type 4 prevents oxi-
dative stress and neurodegeneration. PLoS Biol 8: pii:
e1000479, 2010.
74. Knapp LT and Klann E. Superoxide-induced stimulation
of protein kinase C via thiol modification and modulation
of zinc content. J Biol Chem 275: 24136–24145, 2000.
75. Korichneva I, Hoyos B, Chua R, Levi E, and Hammerling
U. Zinc release from protein kinase C as the common
event during activation by lipid second messenger or re-
active oxygen. J Biol Chem 277: 44327–44331, 2002.
76. Krause KH, Lambeth D, and Kronke M. NOX enzymes as
drug targets. Cell Mol Life Sci 69: 2279–2282, 2012.
77. Kreatsoulas C and Anand SS. The impact of social de-
terminants on cardiovascular disease. Can J Cardiol 26
Suppl C: 8c–13c, 2010.
78. Lapchak PA. A critical assessment of edaravone acute
ischemic stroke efficacy trials: is edaravone an effective
neuroprotective therapy? Expert Opin Pharmacother 11:
1753–1763, 2010.
79. Lau D, Mollnau H, Eiserich JP, Freeman BA, Daiber A,
Gehling UM, Brummer J, Rudolph V, Munzel T, Heit-
zer T, Meinertz T, and Baldus S. Myeloperoxidase
mediates neutrophil activation by association with
CD11b/CD18 integrins. Proc Natl Acad Sci U S A 102:
431–436, 2005.
80. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz
A, Freeman BA, Tarpey M, Fukai T, and Harrison DG.
Endothelial regulation of vasomotion in apoE-deficient
mice: implications for interactions between peroxynitrite
and tetrahydrobiopterin. Circulation 103: 1282–1288,
2001.
81. Leto TL, Morand S, Hurt D, and Ueyama T. Targeting
and regulation of reactive oxygen species generation by
Nox family NADPH oxidases. Antioxid Redox Signal 11:
2607–2619, 2009.
82. Li J, Wang Y, Hu S, Zhou R, Yu X, Wang B, Guan L,
Yang L, Zhang F, and Faraone SV. The monoamine
oxidase B gene exhibits significant association to ADHD.
Am J Med Genet B Neuropsychiatr Genet 147: 370–374,
2008.
83. Lim LC, Powell J, Sham P, Castle D, Hunt N, Murray R,
and Gill M. Evidence for a genetic association between
alleles of monoamine oxidase A gene and bipolar affec-
tive disorder. Am J Med Genet 60: 325–331, 1995.
84. Liu VW and Huang PL. Cardiovascular roles of nitric
oxide: a review of insights from nitric oxide synthase gene
disrupted mice. Cardiovasc Res 77: 19–29, 2008.
85. Mann J and Chiu E. Platelet monoamine oxidase activity
in Huntington’s chorea. J Neurol Neurosurg Psychiatry
41: 809–812, 1978.
86. Martyn KD, Frederick LM, von Loehneysen K, Dinauer
MC, and Knaus UG. Functional analysis of Nox4 reveals
unique characteristics compared to other NADPH oxi-
dases. Cell Signal 18: 69–82, 2006.
87. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M,
Matsuki M, Takai S, Yamanishi K,MiyazakiM,Matsubara
H, and Yabe-Nishimura C. Nox1 is involved in angiotensin
II-mediated hypertension: a study in Nox1-deficient mice.
Circulation 112: 2677–2685, 2005.
88. Maurel A, Hernandez C, Kunduzova O, Bompart G,
Cambon C, Parini A, and Frances B. Age-dependent in-
crease in hydrogen peroxide production by cardiac
monoamine oxidase A in rats. Am J Physiol Heart Circ
Physiol 284: H1460–H1467, 2003.
89. McCord JM. Oxygen-derived free radicals in postischemic
tissue injury. N Engl J Med 312: 159–163, 1985.
90. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO,
Rodrigo J, Rupin A, Verbeuren TJ, Kumar HSA, and
Schmidt HH. Reduced cGMP signaling associated with
neointimal proliferation and vascular dysfunction in late-
stage atherosclerosis. Proc Natl Acad Sci U S A 101:
16671–16676, 2004.
91. Menazza S, Blaauw B, Tiepolo T, Toniolo L, Braghetta P,
Spolaore B, Reggiani C, Di Lisa F, Bonaldo P, and Canton
M. Oxidative stress by monoamine oxidases is causally
involved in myofiber damage in muscular dystrophy. Hum
Mol Genet 19: 4207–4215, 2010.
92. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus
T, Wagner K, Matt S, Gegenbauer K, Geschka S, Karas M,
Stasch JP, Schmidt HH, and Muller-Esterl W. Nitric oxide-
independent vasodilator rescues heme-oxidized soluble
1182 CASAS ET AL.
guanylate cyclase from proteasomal degradation. Circ Res
105: 33–41, 2009.
93. Miller RT, Martasek P, Roman LJ, Nishimura JS, and
Masters BS. Involvement of the reductase domain of
neuronal nitric oxide synthase in superoxide anion pro-
duction. Biochemistry 36: 15277–15284, 1997.
94. Mittal M, Roth M, Konig P, Hofmann S, Dony E, Goyal P,
Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska
G, Kummer W, Klepetko W, Hoda MA, Fink L, Hanze J,
Seeger W, Grimminger F, Schmidt HH, and Weissmann
N. Hypoxia-dependent regulation of nonphagocytic
NADPH oxidase subunit NOX4 in the pulmonary vascu-
lature. Circ Res 101: 258–267, 2007.
95. Montezano AC and Touyz RM. Reactive oxygen species
and endothelial function—role of nitric oxide synthase
uncoupling and Nox family nicotinamide adenine dinu-
cleotide phosphate oxidases. Basic Clin Pharmacol Tox-
icol 110: 87–94, 2012.
96. Murakami N, Ohtsubo T, Kansui Y, Goto K, Noguchi H,
Haga Y, Nakabeppu Y, Matsumura K, and Kitazono T.
Mice heterozygous for the xanthine oxidoreductase gene
facilitate lipid accumulation in adipocytes. Arterioscler
Thromb Vasc Biol 34: 44–51, 2014.
97. Murphy DL, Sims KB, Karoum F, de la Chapelle A, Norio
R, Sankila EM, and Breakefield XO. Marked amine and
amine metabolite changes in Norrie disease patients with
an X-chromosomal deletion affecting monoamine oxi-
dase. J Neurochem 54: 242–247, 1990.
98. Nishino T. The conversion from the dehydrogenase type
to the oxidase type of rat liver xanthine dehydrogenase by
modification of cysteine residues with fluorodini-
trobenzene. J Biol Chem 272: 29859–29864, 1997.
99. Nisimoto Y, Diebold BA, Constentino-Gomes D, and
Lambeth JD. Nox4: a hydrogen peroxide-generating ox-
ygen sensor. Biochemistry 53: 5111–5120, 2014.
100. Nlandu Khodo S, Dizin E, Sossauer G, Szanto I, Martin
PY, Feraille E, Krause KH, and de Seigneux S. NADPH-
oxidase 4 protects against kidney fibrosis during chronic
renal injury. J Am Soc Nephrol 23: 1967–1976, 2012.
101. Odobasic D, Kitching AR, Yang Y, O’Sullivan KM,
Muljadi RC, Edgtton KL, Tan DS, Summers SA, Morand
EF, and Holdsworth SR. Neutrophil myeloperoxidase
regulates T-cell-driven tissue inflammation in mice by
inhibiting dendritic cell function. Blood 121: 4195–4204,
2013.
102. Pullen SS, Lincoln KA, Harrison PC, Chen H, Wang
H, Clifford H, Qian H, Wong D, Sarko C, Brenneman
J, Fryer R, Richman J, Reinhart GA, and Boustany C.
A soluble guanylate cyclase activator protects from
diabetic nephropathy beyond standard of care in the
ZSF1 rat. BMC Pharmacology and Toxicology 2015
16(Suppl): A4
103. Paffenholz R, Bergstrom RA, Pasutto F, Wabnitz P,
Munroe RJ, Jagla W, Heinzmann U, Marquardt A, Bareiss
A, Laufs J, Russ A, Stumm G, Schimenti JC, and Berg-
strom DE. Vestibular defects in head-tilt mice result from
mutations in Nox3, encoding an NADPH oxidase. Genes
Dev 18: 486–491, 2004.
104. Peskin AV, Midwinter RG, Harwood DT, and Winter-
bourn CC. Chlorine transfer between glycine, taurine, and
histamine: reaction rates and impact on cellular reactivity.
Free Radic Biol Med 37: 1622–1630, 2004.
105. Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP,
Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E,
Samano ET, Scalise AV, Muller K, Roessig L, and
Gheorghiade M. Rationale and design of the SOluble
guanylate cyclase stimulatoR in heArT failurE Studies
(SOCRATES). Eur J Heart Fail 16: 1026–1038, 2014.
106. Piret SE, Esapa CT, Gorvin CM, Head R, Loh NY, De-
vuyst O, Thomas G, Brown SD, Brown M, Croucher P,
Cox R, and Thakker RV. A mouse model of early-onset
renal failure due to a xanthine dehydrogenase nonsense
mutation. PLoS One 7: e45217, 2012.
107. Podrez EA, Abu-Soud HM, and Hazen SL.
Myeloperoxidase-generated oxidants and atherosclerosis.
Free Radic Biol Med 28: 1717–1725, 2000.
108. Prakash A, Bharti K, and Majeed AB. Zinc: indications
in brain disorders. Fundam Clin Pharmacol 29: 131–149,
2015.
109. Radermacher KA, Wingler K, Kleikers P, Altenhofer S,
Jr., Hermans J, Kleinschnitz C, and Hhw Schmidt H. The
1027th target candidate in stroke: will NADPH oxidase
hold up? Exp Transl Stroke Med 4: 11, 2012.
110. Radermacher KA, Wingler K, Langhauser F, Altenhofer
S, Kleikers P, Hermans JJ, Hrabe de Angelis M,
Kleinschnitz C, and Schmidt HH. Neuroprotection after
stroke by targeting NOX4 as a source of oxidative stress.
Antioxid Redox Signal 18: 1418–1427, 2013.
111. Ramsay RR. Monoamine oxidases: the biochemistry of
the proteins as targets in medicinal chemistry and drug
discovery. Curr Top Med Chem 12: 2189–2209, 2012.
112. Ribases M, Ramos-Quiroga JA, Hervas A, Bosch R,
Bielsa A, Gastaminza X, Artigas J, Rodriguez-Ben S,
Estivill X, Casas M, Cormand B, and Bayes M. Ex-
ploration of 19 serotoninergic candidate genes in adults
and children with attention-deficit/hyperactivity disorder
identifies association for 5HT2A, DDC and MAOB. Mol
Psychiatry 14: 71–85, 2009.
113. Rodriguez-Munoz M, de la Torre-Madrid E, Sanchez-
Blazquez P, and Garzon J. NO-released zinc supports the
simultaneous binding of Raf-1 and PKCgamma cysteine-
rich domains to HINT1 protein at the mu-opioid receptor.
Antioxid Redox Signal 14: 2413–2425, 2011.
114. Rubinsztein DC, Leggo J, Goodburn S, Walsh C, Jain S,
and Paykel ES. Genetic association between monoamine
oxidase A microsatellite and RFLP alleles and bipolar
affective disorder: analysis and meta-analysis. Hum Mol
Genet 5: 779–782, 1996.
115. Rudolph TK, Rudolph V, Witte A, Klinke A, Szoecs K,
Lau D, Heitzer T, Meinertz T, and Baldus S. Liberation of
vessel adherent myeloperoxidase by enoxaparin improves
endothelial function. Int J Cardiol 140: 42–47, 2008.
116. Sanchez-Blazquez P, Rodriguez-Munoz M, Bailon C, and
Garzon J. GPCRs promote the release of zinc ions medi-
ated by nNOS/NO and the redox transducer RGSZ2 pro-
tein. Antioxid Redox Signal 17: 1163–1177, 2012.
117. Sandler M, Glover V, Clow A, and Jarman J. Monoamine
oxidase-B, monoamine oxidase-B inhibitors, and Parkin-
son’s disease. A role for superoxide dismutase? Adv
Neurol 60: 238–241, 1993.
118. Saura J, Andres N, Andrade C, Ojuel J, Eriksson K, and
Mahy N. Biphasic and region-specific MAO-B response
to aging in normal human brain. Neurobiol Aging 18:
497–507, 1997.
119. Savenkova ML, Mueller DM, and Heinecke JW. Tyrosyl
radical generated by myeloperoxidase is a physiological
catalyst for the initiation of lipid peroxidation in low
density lipoprotein. J Biol Chem 269: 20394–20400, 1994.
ROS-RELATED DISEASES: TARGETS AND INDICATIONS 1183
120. Schappi MG, Jaquet V, Belli DC, and Krause KH. Hy-
perinflammation in chronic granulomatous disease and
anti-inflammatory role of the phagocyte NADPH oxidase.
Semin Immunopathol 30: 255–271, 2008.
121. Schieber M and Chandel NS. ROS function in redox sig-
naling and oxidative stress. Curr Biol 24: R453–R462, 2014.
122. Schmidt HH, Stocker R, Vollbracht C, Paulsen G, Riley DP,
Daiber A, and Cuadrado A. Antioxidants in Translational
Medicine. Antioxid Redox Signal 23: 1130–1143, 2015.
122a. This reference has been deleted.
123. Schmidt HH and Walter U. NO at work. Cell 78: 919–925,
1994.
124. Schroder K, Vecchione C, Jung O, Schreiber JG, Shiri-
Sverdlov R, van Gorp PJ, Busse R, and Brandes RP. Xan-
thine oxidase inhibitor tungsten prevents the development of
atherosclerosis in ApoE knockout mice fed a Western-type
diet. Free Radic Biol Med 41: 1353–1360, 2006.
125. Schuhmacher S, Wenzel P, Schulz E, Oelze M, Mang C,
Kamuf J, Gori T, Jansen T, Knorr M, Karbach S, Hortmann
M, Mathner F, Bhatnagar A, Forstermann U, Li H, Munzel
T, and Daiber A. Pentaerythritol tetranitrate improves an-
giotensin II-induced vascular dysfunction via induction of
heme oxygenase-1. Hypertension 55: 897–904, 2010.
125a. Schulz E, Wenzel P, Munzel T, and Daiber A. Mi-
tochondrial redox signaling: interaction of mitochondrial
reactive oxygen species with other sources of oxidative
stress. Antioxid Redox Signal 20: 308–324, 2014.
126. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B,
Plastre O, Sienkiewicz A, Forro L, Schlegel W, and
Krause KH. NOX4 activity is determined by mRNA
levels and reveals a unique pattern of ROS generation.
Biochem J 406: 105–114, 2007.
127. Sims KB, de la Chapelle A, Norio R, Sankila EM, Hsu
YP, Rinehart WB, Corey TJ, Ozelius L, Powell JF, Bruns
G, et al. Monoamine oxidase deficiency in males with an
X chromosome deletion. Neuron 2: 1069–1076, 1989.
128. Singh C, Bortolato M, Bali N, Godar SC, Scott AL, Chen
K, Thompson RF, and Shih JC. Cognitive abnormali-
ties and hippocampal alterations in monoamine oxidase A
and B knockout mice. Proc Natl Acad Sci U S A 110:
12816–12821, 2013.
129. Stasch JP, Dembowsky K, Perzborn E, Stahl E, and
Schramm M. Cardiovascular actions of a novel NO-
independent guanylyl cyclase stimulator, BAY 41–8543:
in vivo studies. Br J Pharmacol 135: 344–355, 2002.
130. Stasch JP, Schlossmann J, and Hocher B. Renal effects of
soluble guanylate cyclase stimulators and activators: a
review of the preclinical evidence. Curr Opin Pharmacol
21c: 95–104, 2015.
131. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S
AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller
H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B,
Muller-Esterl W, and Schmidt HH. Targeting the heme-
oxidized nitric oxide receptor for selective vasodilatation of
diseased blood vessels. J Clin Invest 116: 2552–2561, 2006.
132. Steinhubl SR. Why have antioxidants failed in clinical
trials? Am J Cardiol 101: 14d–19d, 2008.
133. Stover JF, Belli A, Boret H, Bulters D, Sahuquillo J,
Schmutzhard E, Zavala E, Ungerstedt U, Schinzel R, and
Tegtmeier F. Nitric oxide synthase inhibition with the
antipterin VAS203 improves outcome in moderate and
severe traumatic brain injury: a placebo-controlled ran-
domized Phase IIa trial (NOSTRA). J Neurotrauma 31:
1599–1606, 2014.
134. Sturza A, Leisegang MS, Babelova A, Schroder K, Benkhoff
S, Loot AE, Fleming I, Schulz R, Muntean DM, and Brandes
RP. Monoamine oxidases are mediators of endothelial dys-
function in the mouse aorta.Hypertension 62: 140–146, 2013.
135. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger
DN, Ishii H, Suematsu M, Zweifach BW, and Schmid-
Schonbein GW. Xanthine oxidase activity associated with
arterial blood pressure in spontaneously hypertensive rats.
Proc Natl Acad Sci U S A 95: 4754–4759, 1998.
136. Sydow K and Munzel T. ADMA and oxidative stress.
Atheroscler Suppl 4: 41–51, 2003.
137. Thanan R, Oikawa S, Hiraku Y, Ohnishi S, Ma N, Pinlaor
S, Yongvanit P, Kawanishi S, and Murata M. Oxidative
stress and its significant roles in neurodegenerative dis-
eases and cancer. Int J Mol Sci 16: 193–217, 2014.
138. Tsutsui M, Shimokawa H, Morishita T, Nakashima Y, and
Yanagihara N. Development of genetically engineered
mice lacking all three nitric oxide synthases. J Pharmacol
Sci 102: 147–154, 2006.
139. Van der Schueren BJ, Lunnon MW, Laurijssens BE,
Guillard F, Palmer J, Van Hecken A, Depre M, Vanmolkot
FH, and de Hoon JN. Does the unfavorable pharmacoki-
netic and pharmacodynamic profile of the iNOS inhibitor
GW273629 lead to inefficacy in acute migraine? J Clin
Pharmacol 49: 281–290, 2009.
140. Villeneuve C, Guilbeau-Frugier C, Sicard P, Lairez O,
Ordener C, Duparc T, De Paulis D, Couderc B, Spreux-
Varoquaux O, Tortosa F, Garnier A, Knauf C, Valet P,
Borchi E, Nediani C, Gharib A, Ovize M, Delisle MB,
Parini A, and Mialet-Perez J. p53-PGC-1alpha pathway
mediates oxidative mitochondrial damage and cardio-
myocyte necrosis induced by monoamine oxidase-A
upregulation: role in chronic left ventricular dysfunction
in mice. Antioxid Redox Signal 18: 5–18, 2013.
141. von Leitner EC, Klinke A, Atzler D, Slocum JL, Lund N,
Kielstein JT, Maas R, Schmidt-Haupt R, Pekarova M,
Hellwinkel O, Tsikas D, D’Alecy LG, Lau D, Willems S,
Kubala L, Ehmke H, Meinertz T, Blankenberg S,
Schwedhelm E, Gadegbeku CA, Boger RH, Baldus S, and
Sydow K. Pathogenic cycle between the endogenous nitric
oxide synthase inhibitor asymmetrical dimethylarginine
and the leukocyte-derived hemoprotein myeloperoxidase.
Circulation 124: 2735–2745, 2011.
142. Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T, Neu-
mayer HH, and Peters H. Stimulation of soluble guanylate
cyclase improves renal recovery after relief of unilateral
ureteral obstruction. J Urol 186: 1142–1149, 2011.
143. Wang-Rosenke Y, Mika A, Khadzhynov D, Loof T,
Neumayer HH, and Peters H. Impact of biological gender
and soluble guanylate cyclase stimulation on renal re-
covery after relief of unilateral ureteral obstruction. J Urol
188: 316–323, 2012.
144. Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA,
and Ascherio A. Plasma urate and risk of Parkinson’s
disease. Am J Epidemiol 166: 561–567, 2007.
145. Weitzdoerfer R, Hoeger H, Engidawork E, Engelmann M,
Singewald N, Lubec G, and Lubec B. Neuronal nitric
oxide synthase knock-out mice show impaired cognitive
performance. Nitric Oxide 10: 130–140, 2004.
146. Whibley A, Urquhart J, Dore J, Willatt L, Parkin G, Gaunt
L, Black G, Donnai D, and Raymond FL. Deletion of
MAOA and MAOB in a male patient causes severe de-
velopmental delay, intermittent hypotonia and stereotypical
hand movements. Eur J Hum Genet 18: 1095–1099, 2010.
1184 CASAS ET AL.
147. Wilkinson-Berka JL,Deliyanti D, Rana I,Miller AG, Agrotis
A, Armani R, Szyndralewiez C, Wingler K, Touyz RM,
CooperME, Jandeleit-DahmKA, and Schmidt HH. NADPH
oxidase, NOX1, mediates vascular injury in ischemic reti-
nopathy. Antioxid Redox Signal 20: 2726–2740, 2014.
148. Wind S, Beuerlein K, Armitage ME, Taye A, Kumar AH,
Janowitz D, Neff C, Shah AM, Wingler K, and Schmidt
HH. Oxidative stress and endothelial dysfunction in aortas
of aged spontaneously hypertensive rats by NOX1/2 is
reversed by NADPH oxidase inhibition. Hypertension 56:
490–497, 2010.
149. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, Ar-
mitage ME, Ho H, Schmidt HH, and Wingler K. Compara-
tive pharmacology of chemically distinct NADPH oxidase
inhibitors. Br J Pharmacol 161: 885–898, 2010.
150. Winterbourn CC and Kettle AJ. Biomarkers of
myeloperoxidase-derived hypochlorous acid. Free Radic
Biol Med 29: 403–409, 2000.
151. This reference has been deleted.
152. Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, Li Y, Chen YT, Yin
F, Liao CP, Stiles BL, Zhau HE, Shih JC, and Chung LW.
Monoamine oxidase A mediates prostate tumorigenesis and
cancer metastasis. J Clin Invest 124: 2891–2908, 2014.
153. Xia Y and Zweier JL. Direct measurement of nitric oxide
generation from nitric oxide synthase. Proc Natl Acad Sci
U S A 94: 12705–12710, 1997.
154. Youdim MB, Edmondson D, and Tipton KF. The thera-
peutic potential of monoamine oxidase inhibitors. Nat Rev
Neurosci 7: 295–309, 2006.
Address correspondence to:
Ana I. Casas
Department of Pharmacology
Cardiovascular Research
Institute Maastricht (CARIM)
Maastricht University
Maastricht
The Netherlands
E-mail: a.casasguijarro@maastrichtuniversity.nl
Dr. Harald H. H. W. Schmidt
Department of Pharmacology
Cardiovascular Research
Institute Maastricht (CARIM)
Maastricht University
Maastricht
The Netherlands
E-mail: h.schmidt@maastrichtuniversity.nl
Date of first submission to ARS Central, June 30, 2015; date
of final revised submission, October 6, 2015; date of accep-
tance, October 6, 2015.
Abbreviations Used
ADMA¼ asymmetric dimethyl-l-arginine
apo-sGC¼ heme-free soluble guanylate cyclase
H4B¼ tetrahydrobiopetrin
cGMP¼ nicotinamide adenine dinucleotide
phosphate
CVD¼ cardiovascular disease
CGD¼ chronic granulomatous disease
DUOX¼ dual oxidase
eNOS¼ endothelial nitric oxide synthase
FAD¼ flavin adenine dinucleotide
H2O2¼ hydrogen peroxide
IC50¼ half-maximal inhibitory concentration
iNOS¼ inducible nitric oxide synthase
Km¼Michaelis constant
KO¼ knockout
LPO¼ lipid peroxidase
MAO¼monoamine oxidases
MPO¼myeloperoxidase
NAD¼ nicotinamide adenine dinucleotide
NADPH¼ nicotinamide adenine dinucleotide
phosphate
H4N¼ tetrahydroneopterin
nNOS¼ neuronal nitric oxide synthase
NO¼ nitric oxide
NOS¼ nitric oxide synthase
NOS1¼ nitric oxide synthase 1
NOS2¼ nitric oxide synthase 2
NOX¼ nicotinamide adenine dinucleotide
phosphate oxidases
Nrf2¼ nuclear factor (erythroid-derived 2)-
like 2
O2
-¼ superoxide anion
PAH¼ pulmonary arterial hypertension
ROS¼ reactive oxygen species
sGC¼ soluble guanylate cyclase
sGCa¼ soluble guanylate cyclase activators
sGCs¼ soluble guanylate cyclase stimulators
uc-eNOS¼ uncoupled endothelial nitric oxide
synthase
XO¼ xanthine oxidase
XOi¼ xanthine oxidase inhibitors
XDH¼ xanthine dehydrogenase
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